Regulatory & approvals
FDA / EMA decisions, breakthrough designations and post-marketing safety actions in PD.
State of the art
No update yet for Regulatory & approvals. An update is a standalone state-of-the-art for the topic — what someone with Parkinson's needs to know about where this approach stands today.
-
With new FDA green light for developer, Parkinson’s clinical trial to launch soon
The FDA authorized Gain Therapeutics' Investigational New Drug (IND) application for GT-02287, clearing the way for a Phase 2 trial to begin between July and September 2026 across US, Australian, and European sites.